Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT01138085 |
Title | Safety, Pharmacokinetics (PK) of AKT and MEK Combination |
Recruitment | Completed |
Gender | both |
Phase | Phase I |
Variant Requirements | Yes |
Sponsors | GlaxoSmithKline |
Indications | |
Therapies | |
Age Groups: | adult |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
GSK Investigational Site | Aurora | Colorado | 80045 | United States | Details | |
GSK Investigational Site | New Haven | Connecticut | 06520 | United States | Details | |
GSK Investigational Site | Boston | Massachusetts | 02114 | United States | Details | |
GSK Investigational Site | Boston | Massachusetts | 02215 | United States | Details | |
GSK Investigational Site | New Brunswick | New Jersey | 08901 | United States | Details | |
GSK Investigational Site | Nashville | Tennessee | 37232 | United States | Details | |
GSK Investigational Site | Dallas | Texas | 75246 | United States | Details | |
GSK Investigational Site | Houston | Texas | 77230-1439 | United States | Details | |
GSK Investigational Site | San Antonio | Texas | 78229 | United States | Details | |
GSK Investigational Site | Salt Lake City | Utah | 84112-5550 | United States | Details |